EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC

Vitalay Fomin, WeiQing Venus So, Richard Alex Barbieri, Kenley Hiller-Bittrolff, Elina Koletou, Tiffany Tu, Bruno Gomes, James Cai, Jehad Charo

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-009092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Vitalay Fomin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharmaceutical Research and Early Development, Data & Analytics, Roche Innovation Center New York, Little Falls, New Jersey, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Machine Learning, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (CPIs) have revolutionized cancer therapy for several tumor indications. However, a substantial fraction of patients treated with CPIs derive no benefit or have short-lived responses to CPI therapy. Identifying patients who are most likely to benefit from CPIs and deciphering resistance mechanisms is therefore essential for developing adjunct treatments that can abrogate tumor resistance. Patients and methods In this study, we used a machine learning approach that used the US-based nationwide de-identified Flatiron Health and Foundation Medicine non-small cell lung carcinoma (NSCLC) clinico-genomic database to identify genomic markers that predict clinical responses to CPI therapy. In total, we analyzed data from 4,433 patients with NSCLC.

Results

Analysis of pretreatment genomic data from 1,511 patients with NSCLC identified. Of the 36 genomic signatures identified, 33 exhibited strong predictive capacity for CPI response (n=1150) compared with chemotherapy response (n=361), while three signatures were prognostic. These 36 genetic signatures had in common a core set of four genes ( BRAF, BRIP1, FGF10, and FLT1 ). Interestingly, we observed that some (n=19) of the genes in the signatures (eg, TP53, EZH2, KEAP1 and FGFR2 ) had alternative mutations with contrasting clinical outcomes to CPI therapy. Finally, the genetic signatures revealed multiple biological pathways involved in CPI response, including MAPK, PDGF, IL-6 and EGFR signaling.

Conclusions

In summary, we found several genomic markers and pathways that provide insight into biological mechanisms affecting response to CPI therapy. The analyses identified novel targets and biomarkers that have the potential to provide candidates for combination therapies or patient enrichment strategies, which could increase response rates to CPI therapy in patients with NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungMachine LearningImmune Checkpoint InhibitorsLung NeoplasmsMutationDrug Resistance, NeoplasmHumansFemaleMaleBiomarkers, TumorMiddle AgedAged

Stichwörter der Autor:innen

BiomarkerGenomeImmune Checkpoint InhibitorLung Cancer

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Roche Pharmaceutical Research and Early Development, Data & Analytics, Roche Innovation Center New York, Little Falls, New Jersey, USA.
  • Numenos, New York, NY, USA.
  • Data Science, Capgemini Engineering, Paris, France.
  • Roche Pharmaceutical Research and Early Development, Data and Analytics, Roche Innovation Center Basel, Basel, Switzerland.
  • Roche Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.
  • Roche Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland jehad.charo@roche.com.

Förderung

  • Roche

Zitieren

APA

Fomin, V., So, W. V., Barbieri, R. A., Hiller-Bittrolff, K., Koletou, E., Tu, T., Gomes, B., Cai, J., & Charo, J. (2025). Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009092

Vancouver

Fomin V, So WV, Barbieri RA, Hiller-Bittrolff K, Koletou E, Tu T, et al. Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-009092

BibTeX
@article{Fomin2025,
  author = {Fomin, Vitalay and So, WeiQing Venus and Barbieri, Richard Alex and Hiller-Bittrolff, Kenley and Koletou, Elina and Tu, Tiffany and Gomes, Bruno and Cai, James and Charo, Jehad},
  title = {Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-009092}
}
Kostenlos starten →